Oculis Holding AG (OCS) Non-Current Assets (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Non-Current Assets came in at $21.7 million in Q1 2026, up 26.56% year-on-year from $17.1 million in Q1 2025, and up 1.36% quarter-over-quarter from $21.4 million in Q4 2025.
Oculis Holding AG (OCS) Non-Current Assets (2021 - 2026) Analysis & Trends
Oculis Holding AG's Non-Current Assets history runs 6 years deep, the most recent figure standing at $21.7 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 26.56% year-over-year to $21.7 million in Q1 2026; TTM through Mar 2026 was $21.7 million, a 26.56% increase from a year earlier, with the FY2025 full-year figure at $20.6 million, up 17.22% from the prior year.
- Non-Current Assets rose to $21.7 million in Q1 2026 per OCS's latest filing, from $21.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $21.7 million in Q1 2026 and bottomed at $13.9 million in Q4 2022.
- The 5-year median for Non-Current Assets is $16.3 million (2024), against an average of $17.2 million.
- Across the five-year window, Non-Current Assets gained 4.02% in 2024 and rose 29.88% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $13.9 million in 2022, then grew by 8.08% to $15.0 million in 2023, then grew by 17.34% to $17.6 million in 2024, then advanced by 21.08% to $21.4 million in 2025, then climbed by 1.36% to $21.7 million in 2026.
- Per Business Quant, the three latest OCS Non-Current Assets figures stand at $21.7 million (Q1 2026), $21.4 million (Q4 2025), and $21.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 910.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.65 Mn |
| Dec 31, 2025 | 21.36 Mn |
| Sep 30, 2025 | 21.16 Mn |
| Jun 30, 2025 | 18.63 Mn |
| Mar 31, 2025 | 17.11 Mn |
| Dec 31, 2024 | 17.64 Mn |
| Sep 30, 2024 | 16.29 Mn |
| Jun 30, 2024 | 15.59 Mn |
| Mar 31, 2024 | 15.20 Mn |
| Dec 31, 2023 | 15.04 Mn |
| Sep 30, 2023 | 15.22 Mn |
| Jun 30, 2023 | 14.99 Mn |
| Dec 31, 2022 | 13.91 Mn |
| Dec 31, 2021 | 10.91 Mn |